The study will be conducted at 2 study centers in Germany.~Eligible participants will be randomized to one of the 8 treatment sequences (4 unique sequences to Group 1 and 4 unique sequences to Group 2). In Group 1, participants will receive 5 single dose treatments, while in Group 2 participants will receive 4 single dose treatments.~Below treatments A, B, C, D and E will be given to participants in Group 1 and treatments A, F, G and H will be given to participants in Group 2 in randomized order:~Treatment A: AZD9977 Dose A + 10 mg dapagliflozin tablet, fasted~Treatment B: AZD9977 Dose A + 10 mg dapagliflozin capsule 1, fasted~Treatment C: AZD9977 Dose A + 10 mg dapagliflozin capsule 1, fed~Treatment D: AZD9977 Dose A + 10 mg dapagliflozin capsule 2, fasted~Treatment E: AZD9977 Dose A + 10 mg dapagliflozin capsule 2, fed~Treatment F: AZD9977 Dose A + 10 mg dapagliflozin capsule 3, fasted~Treatment G: AZD9977 Dose A + 10 mg dapagliflozin capsule 4, fasted~Treatment H: 10 mg dapagliflozin capsule, fasted~The study will comprise of the following:~A screening period of maximum 21 days.~Four or five treatment periods during which participants will be resident at the study center from the day before dosing until at least 72 hours after the final dose.~A final visit within 5 to 7 days after administration of the last treatment.~Each participant will receive single dose treatments under fasted or fed conditions, separated by at least 4 days washout.~Each participant will be involved in the study for approximately 6 to 7 weeks.
The primary purpose of the study is to evaluate relative bioavailability of AZD9977 and dapagliflozin and compare the plasma concentration time profiles after dosing with different capsule formulations containing both AZD9977 and dapagliflozin or solely dapagliflozin, the AZD9977 capsule, and dapagliflozin tablet under fasted conditions.